Over in Beijing, scientists have developed a revolutionary new gene therapy that can reverse some of the effects of aging in mice and extend their lifespans. These findings could quite promisingly be used in humans in the near future if all goes well.
The method, detailed in a paper in the Science Translational Medicine journal earlier this month, involves inactivating a gene called kat7 which the scientists found to be a key contributor to cellular aging.
The specific therapy they used and the results were a world first, said co-supervisor of the project Professor Qu Jing, 40, a specialist in aging and regenerative medicine from the Institute of Zoology at the Chinese Academy of Sciences (CAS). “These mice show after 6-8 months overall improved appearance and grip strength and most importantly they have an extended lifespan for about 25 percent,” Qu said.
The team of biologists from different CAS departments used the CRISPR/Cas9 method to screen thousands of genes for those which were particularly strong drivers of cellular senescence, the term used to describe cellular aging. They identified 100 genes out of about 10,000, and kat7 was the most efficient at contributing to senescence in cells, Qu said.
“We just tested the function of the gene in different kinds of cell types, in the human stem cell, the mesenchymal progenitor cells, in the human liver cell, and the mouse liver cell, and for all of these cells we didn’t see any detectable cellular toxicity. And for the mice, we also didn’t see any side effects yet.”
Despite this, the method is a long way from being ready for human trials, Qu said.
“It’s still definitely necessary to test the function of kat7 in other cell types of humans and other organs of mice and in the other pre-clinical animals before we use the strategy for human aging or other health conditions,” she said.
Qu said she hopes to be able to test the method on primates next, but it would require a lot of funding and much more research first. “In the end, we hope that we can find a way to delay aging even by a very minor percentage…in the future.”